First data on CRP apheresis within the CAMI1 study published

29.03.2019

First data on the treatment of myocardial infarction patients were published in the journal Therapeutic Apheresis and Dialysis.

This publication presents the results of the use of PentraSorb® CRP after myocardial infarction in the CAMI study from a small group of patients. Treatment of 13 patients after acute myocardial infarction (STEMI) with at least two CRP aphereses each was well tolerated by all patients and described as safe. Selective CRP apheresis depleted CRP by a mean of more than 50% and thus significantly reduced blood CRP concentrations.